Pyridoxine

Educational overview

Oral supplement and prescription injection; chronic high exposure can cause sensory neuropathy.

Pyridoxine is the most common supplemental form of vitamin B6, a water-soluble vitamin that the liver converts to pyridoxal 5'-phosphate (PLP), the coenzyme for more than a hundred reactions in amino-acid metabolism, neurotransmitter synthesis, haemoglobin formation, and glycogen breakdown. Pyridoxal and pyridoxamine are the other natural vitamers, and some supplements sell PLP directly as an "active" form. Frank deficiency is uncommon in high-income countries but occurs with alcohol dependence, malabsorption, kidney disease, and several medicines, notably isoniazid, which is why the two are co-prescribed. Pyridoxine is sold as an oral supplement, appears in nearly every multivitamin and B-complex, and exists as a prescription injection for intramuscular or intravenous administration.

Requirements and deficiency biology are well established from controlled depletion studies and population data summarised by the NIH Office of Dietary Supplements. Trials of pyridoxine for premenstrual symptoms, nausea in pregnancy, carpal tunnel syndrome, and cardiovascular prevention via homocysteine lowering have produced mixed or null results. The best-documented finding is toxicity: in 1983 Schaumburg and colleagues described a sensory neuropathy with ataxia in adults taking gram-level amounts, and later reports, the European Food Safety Authority's 2023 review, and Australian pharmacovigilance data show neuropathy at far lower intakes, particularly from several overlapping products. A 2017 in-vitro study proposed a mechanism in which pyridoxine itself competitively inhibits PLP-dependent enzymes, so that excess creates a functional deficiency.

In the United States, oral pyridoxine is a dietary supplement, while Pyridoxine Hydrochloride Injection USP is an FDA-approved prescription drug indicated for deficiency states, drug-induced deficiency, inborn errors such as B6-dependent seizures, and isoniazid poisoning when oral administration is not feasible. Its label carries an aluminum warning for prolonged parenteral exposure in impaired kidney function and states that it antagonises levodopa given without carbidopa. Compounded B6 appears mostly inside injectable B-complex blends rather than alone. Regulators outside the United States have moved to restrict supplemental B6: Australia's TGA lowered the labelling threshold for a neuropathy warning in 2022 and later announced rescheduling of higher-strength oral products, and EFSA set a tolerable upper level well below earlier US figures.

The injection is labelled for controlled room temperature with protection from light and is a clear solution that is discarded if discoloured. Oral products are stable in a closed container away from heat and moisture. For record-keeping, the relevant points are the total daily B6 across every product, since multivitamins, B-complexes, magnesium and zinc products, and energy drinks often contribute without being obvious, and the duration of use, because neuropathy risk relates to cumulative exposure. New tingling, numbness, or unsteadiness dated against the supplement record is the observation clinicians look for, and serum PLP or pyridoxine levels can confirm high exposure. Levodopa, isoniazid, and cycloserine are the medicines most relevant to note alongside it.

Category

Vitamin

Routes represented

Oral / Subcutaneous (SubQ)

Storage context

Follow the product or pharmacy label; requirements vary by route and formulation.